Imaging mass spectrometry for spatial metabolomics by Boughton, B. & Roessner, U.
Vol 46 No 3 December 2015 Page 9AUSTRALIAN BIOCHEMIST
I n t roduc t i on
Over the past decade, mass spectrometry (MS) has seen 
major technical advances that have increased the scope, 
applicability and adoption of the technology in a vast array 
of research areas (1). The application of MS to biochemical 
imaging via imaging mass spectrometry (IMS) has 
emerged as one of the leading spatial analysis technologies 
in biological systems. There are many recent excellent 
comprehensive reviews of IMS (1-13). In this article we 
provide an introduction to matrix-assisted laser desorption 
ionisation (MALDI) IMS. The ‘omics technologies – 
genomics, transcriptomics, proteomics and metabolomics 
(and others) – have provided insights into biochemistry, 
physiology and biology and are at the forefront of 
discovery in modern systems biology (14). Colloquially, 
the potential of the genome is described in the statement 
“What could happen,” the transcriptome “What appears 
to be happening,” the proteome “What’s doing the work,” 
and the metabolome “What is currently happening and 
what has already happened.” The exquisite specialisation 
and compartmentalisation of biological systems require 
spatial approaches to allow examination of “Where things 
are happening” to unveil the underlying biology.
In the past, spatial analysis has been conducted using 
a number of different techniques, which can be broadly 
categorised into two approaches: 1) in vitro isolation and 
extraction of individual tissue/cell types and 2) in situ, 
including in vivo, analysis using an imaging approach. 
The suite of technologies available for in situ imaging 
is enormously powerful and varied; including Fourier 
transform infra-red spectroscopy, magnetic resonance 
imaging, electron microscopy, and histochemical and 
immunolabelling approaches coupled with optical and 
fluorescence microscopy. Each approach takes advantage 
of different physical and chemical properties of the 
underlying tissue to provide unique insights. IMS has a 
number of advantages which are directly derived from the 
capabilities of modern MS instrumentation, which provide 
molecular specificity, high sensitivity, and the ability to 
measure a broad range of analytes at high mass resolving 
power with high mass accuracy across wide mass ranges. 
IMS can provide very high lateral resolution, enabling 
molecular distinction across fine morphological features 
within tissues. 
Although the concept of using MS for imaging was 
introduced in 1962 (secondary ion mass spectrometry, 
SIMS), it was not until the mid-’90s, with the introduction 
of soft ionisation techniques, in particular MALDI, that 
IMS began to be applied to the biosciences (15,16). IMS 
has advanced using a variety of different ion sources 
and approaches. It has found extensive use in molecular 
pathology and histology where the technique is used to 
map the spatial distribution of proteins and small molecules 
(including drugs, lipids and endogenous metabolites) 
within tissues (1,12). IMS has been demonstrated to have 
a number of advantages, including a label-free analysis 
and the simultaneous multiplex measurement of hundreds 
to possibly thousands of analytes in a single imaging 
experiment, providing rich, high density multidimensional 
data. Combination of IMS with advanced software and data 
analysis techniques now allows the virtual microdissection 
and interrogation of the molecular makeup of individual 
tissues. Lately, advances in spatial resolution have placed 
IMS at the forefront of single cell metabolomics (17,18).
Imag ing  Mas s  Spe c t rometr y
There are four steps in a basic IMS experiment: 1) sample 
selection and preparation, 2) desorption and ionisation, 3) 
mass-analysis and 4) image registration and data analysis. 
Careful control of each is essential to enable generation 
of high quality images. In particular, sample selection, 
storage and preparation has a disproportionate impact 
on the final results; many sample preparation steps or 
techniques have the potential to contaminate the tissue 
section with exogenous material, affecting reproducibility, 
ionisation and image quality. Fundamentally, the IMS 
process involves placing a suitable tissue section into an ion 
source, ionising the sample and collecting a series of mass 
spectra. This series of individual mass spectra is collected 
in a two dimensional (2D) array across the tissue section or 
the surface of a tissue using one of a range of different ion 
sources and mass analysers. The most common approach is 
a microprobe approach where for each spatial coordinate, 
a single corresponding mass spectrum is collected. The 
resulting mass spectra represent the ionisable molecules 
present as their mass-to-charge ratios (m/z) that are then 
correlated with a high resolution optical image of the tissue 
or histochemical stain, with each spectrum assigned as an 
individual pixel for image generation. When the intensity 
value of each ion is plotted as an intensity map across the 
2D array, the resultant reconstructed ion image represents 
the spatial distribution of the corresponding molecule(s). 
Three dimensional (3D) approaches are also possible, 
where serial 2D arrays from sequential tissue sections (or 
depth profiling) from the one tissue sample are measured 
and then used for computational reconstruction of a 3D 
volume.
I on i za t i on  and  Mas s  Ana ly s i s
IMS relies on the ability to form ions that are then 
transferred under vacuum and measured by the mass 
analyzer (Fig. 1). Currently, the dominant ion source and 
approach is MALDI, owing to a range of commercial 
instruments that display high spatial and mass resolutions, 
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ease of use and a broad range of applicability to a variety 
of biological applications. In practice, lateral resolutions 
for MALDI instruments are in the 5–50 µm range. The past 
three to five years has seen an explosion in the availability 
of different different types of ion sources, particularly 
specialised sources for ambient ionisation conditions (19). 
Further, a number of popular alternative ion sources exist, 
including SIMS, desorption electrospray ionisation (DESI), 
and laser ablation electrospray ionisation (LAESI). When 
operating IMS instruments at very high spatial resolutions, 
there is also a significant trade-off against sensitivity: as the 
sampling area decreases, the total number of ions decreases, 
and the overall sensitivity for individual ions decreases. 
Advanced mass analysers and detectors are now allowing 
the measurement of very low numbers of ions, which to 
some degree mitigates losses in sensitivity at high lateral 
resolution. 
The mass analyser is the core component of a MS, 
enabling determination of the m/z of an ion. The type of 
mass analyser used and the spectral resolution achievable 
also has a direct impact on the ability to conduct IMS 
experiments. Types of mass analysers used in IMS 
instruments include: 1) unit resolution, encompassing 
quadrupole and ion-trap technologies, typically a linear 
ion trap; 2) accurate mass, including time-of-flight (TOF) 
instruments; and 3) Fourier transform (FT), encompassing 
both Orbitrap and FT ion cyclotron resonance (FT-ICR) 
instruments. For metabolites, there is a clear need for 
accurate mass and high mass resolving instruments and/
or the use of tandem MS to distinguish between differing 
metabolites in tissues. Low mass resolution instruments 
can lead to misidentification or misinterpretation due to an 
inability to resolve peaks of similar mass. IMS experiments 
are less sensitive than analyses that orthogonally separate 
analytes prior to measurement and detection; this is 
directly due to the complexity of biological tissues, where 
vast concentration ranges of chemical entities are present 
with differing chemistries and molecular sizes (e.g. 
proteins, lipids, organic acids, amino acids, carbohydrates, 
inorganic ions etc.). For MALDI experiments, the presence 
of high abundance, low molecular weight ions generated 
directly from the matrix constitute significant interfering 
signals. The ability of a MS to distinguish one mass peak 
from another peak close in mass is described by both 
mass resolution and resolving power (RP). Higher mass 
resolution allows easier identification of contributing ions 
and exclusion of interference from the presence of other 
chemical entities. Higher mass RP is essential for high mass 
accuracy, whereby a higher RP allows identification of the 
centre of the peak and determination of the mass error, 
with low mass error allowing unambiguous assignment 
of a molecular formula, aiding in identification. Modern 
high resolution instruments are capable of <10 parts 
per million (ppm) mass error for TOF and <2 ppm mass 
error for FT instruments. Measurements conducted on 
low mass resolution instruments are typically operated 
in a targeted tandem MS approach to provide molecular 
selectivity where specific fragment ions of single analytes 
are monitored, providing both molecular specificity and 
increased sensitivity. IMS measurements using higher 
resolution detectors provide the ability to unambiguously 
resolve a peak from the complex spectra that are generated, 
allowing untargeted profiling type techniques. 
A hybrid approach that uses ion mobility coupled to 
mass spectrometry (IM-MS) that first separates ions by 
their mobility in a carrier gas followed by detection by 
Fig. 1A. Laser desorption ionisation (LDI) 
approach versus matrix-assisted laser 
desorption ionisation (MALDI) approach. 
For LDI, no matrix is applied and ions 
are generated by directly ablating tissue, 
relying upon the presence of endogenous 
UV absorbing molecules to aid desorption. 
For MALDI, a thin layer of chemical matrix 
is applied across the surface of the tissue. 
The matrix preferentially absorbs the UV 
light, desorbing analytes from the surface.
B. Results showing the distribution of 
a number of different Eucalyptus species 
metabolites  generated using LDI. 
Metabolites can be mapped to the oil 
glands (secretory cavities), general leaf 
tissue and vasculature. Data generated 
on a 7T Bruker SolariX fourier transform 
ion cyclotron mass spectrometer. Images 
generated using FlexImaging 4.1.
A)
B)
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Distribution of metabolites and lipids in Eucalypt leaf.
Overlay
Oil Gland Leaf Tissue Vasculature
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MS has recently been developed (20,21 and previous 
article). IM-MS offers the ability to orthogonally separate 
ions in the gas phase with similar m/z but different shapes 
via collisional cross section (CCS), providing a number of 
benefits including better signal-to-noise and the potential to 
separate isomers according to their shape and charge. The 
application of IM-MS to MALDI-IMS experiments provides 
much promise for the analysis of large lipids, peptides and 
proteins; however, the benefits of IM-MS for small molecule 
analysis are still being assessed.
App l i ca t i on s
MALDI-IMS has been used extensively in biomedical 
research with hundreds of studies published. More recently, 
interest in mapping the distribution of plant metabolites 
has taken off with around 80 publications focused on plant 
secondary metabolites, primary metabolism, disease states 
and environmental interactions. We have developed a 
number of methods to examine plant metabolites using a 
laser desorption ionisation (LDI) approach in Eucalyptus 
species (Fig. 1B). The LDI approach (22) relies upon the 
natural abundance of UV-absorbing plant secondary 
metabolites to enhance ionisation directly from tissue. 
Using LDI, we have been able to map the distribution of 
a number of different plant metabolites, including non-
volatile oleuropeyl-glucose esters and flavonones, to the 
extracellular domain of leaf secretory cavities (oil glands) 
(23). The secretory cavities of Eucalyptus species are 
characterised by their distinctive composition of volatile 
terpenes and a layer of non-volatile components directly 
adjacent to highly metabolically active secretory cells. 
The non-volatile components have been hypothesised 
to provide a potential buffer against auto-toxic terpenes. 
Our LDI data show distinct colocalisation of a number 
of different oleuropeyl-glucose esters to the edges of the 
secretory cavities of sectioned leaf, confirming previous 
results generated from fluorescence imaging and laborious 
manual collection, extraction and MS analysis of secretory 
cavity content.
More recently, we have developed new matrices 
and analytical techniques to examine lipids, including 
glycerophospholipids and unstable glycosphingolipids in 
mammalian tissues (Figs. 2, 3). Using high mass resolution 
MALDI-IMS on a Bruker Solarix FT-ICR-MS, we have been 
able to distinguish different lipid classes, including elusive 
sulfatides that are similar in mass to phosphatidylserine 
(Fig. 2). Gangliosides are high mass glycosphingolipids 
that are found in relatively high concentrations in neurons 
and are directly involved in or implicated in a number 
of different disease states including Tay-Sachs disease, 
Fabry’s disease, Alzheimer’s, Guillain-Barré syndrome 
and during infection by pathogens that cause conditions 
such as botulism, cholera and influenza, amongst others. 
Gangliosides are built upon a core ceramide backbone 
conjugated to a variable oligosaccharide, which is typically 
made up of a number of hexose units (e.g. galactose, glucose, 
hexosamines and N-acetyl-hexosamines), and sialic acid 
(N-acetylneuraminic acid). Previous MALDI approaches 
using traditional matrices lead to in-source fragmentation 
and loss of sialic acid residues or do not display sufficient 
sensitivity to observe very low abundant acetylated species 
(24,25). Our research has shown an increase in the total 
number of glycosphingolipids observed and increased 
sensitivity for low abundant species (Fig. 3A). Using an 
experimental proton sponge analogue to measure lipids in 
rat brain we have been able to observe the major ganglioside 
species GM1 and GD1, and an acetylated GD1 species (Fig. 
3B). In total, we were able to tentatively identify by accurate 
mass (<5 ppm mass error using SimLipid 4.3 software 
(Premier Biosoft, Palo Alto, CA, USA)) up to 69 different 
Fig. 2A. Distribution of two lipid species with similar masses in coronal sections of rat brain, displaying 
vastly different signal intensities and spatial distributions. Tentative identification by accurate mass match 
(<5 ppm mass error) using SimLipid 4.3 (Premier BioSoft). Blue – PS(40:6) = phosphatidylserine (40:6), 
m/z = 834.5293 (-0.29 ppm mass error); red – (3’-sulfo)-Galβ-ceramide (38:1) = N-eicosanoyl-1-β-(3’-sulfo)-
glucosyl-sphing-4-enine, m/z = 834.5786 (-1.85 ppm mass error).
B. Mass spectra showing difference in response of PS(40:6) (blue) and (3’-sulfo)-Galβ-ceramide (38:1) (red). 
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glycosphingolipids, ceramides, sphingomyelin, sphingoid 
bases and sulfatides, providing much promise for future 
spatial ganglioside research.
Conc lu s i on
MALDI-IMS has demonstrated applications in a vast 
range of spatial biochemical and metabolomics research. 
The application of ultra-high resolution and high mass 
accuracy MS provides the ability to distinguish molecular 
species very close in mass and accurately determine 
molecular formula. The rich, multidimensional and highly 
dense data are currently providing unique insights into the 
vast chemical complexity and specialisation found within 
biological systems that is not possible using other methods. 
With the technology and approaches now established in 
the Australian research community the future looks very 
promising.
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Fig. 3A. Average mass spectra of high mass lipid range, m/z 1540–1575, displaying ions for a range of 
tentatively identified gangliosides (SimLipid 4.3). Red – GM1(18:1/18:0), m/z = 1544.875 (-4 ppm mass error); 
and green – GM1(20:1/18:0), m/z = 1572.901 (-1 ppm mass error).
B.  Average mass spectra of high mass lipid range, m/z 1840-1900, displaying ions for a range of tentatively 
identified gangliosides (SimLipid 4.3) Pink – GD1(20:1/18:0), m/z = 1857.956 (-12 ppm mass error); and blue – 
9-Oac-GD1(20:1/18:0), m/z = (-7 ppm mass error).
C.  Distribution of respective gangliosides in rat brain coronal section. GM1(18:1/18:0) and GM1(20:1/18:0) 
signal intensity scaled 0–100%, GD1 signal intensity scaled 0–50%, 9-OAc-GD1 signal intensity scaled 0–30%. 
Data generated on a 15T Bruker SolariX FT-ICR-MS. Images generated using FlexImaging 4.1.
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